Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity

Prashanth Kanagarajah, Rajinikanth Ayyathurai, Daniel J. Caruso, Christopher Gomez, Angelo E. Gousse

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background To evaluate the efficacy of intradetrusor botulinum toxin-A (BTX-A) in idiopathic overactive bladder patients (OAB) refractory to antimuscarinic therapy, without detrusor overactivity (DOA) on urodynamics. Methods Patients with refractory idiopathic OAB without DOA on urodynamics were prospectively enrolled. Subjects completed a 3-day voiding diary (3-VD), urogenital distress inventory-6 questionnaire (UDI-6) and graded their quality of life on a 10-cm visual analog scale (VAS) prior to study enrollment and at week 12 postinjection. All patients underwent multichannel urodynamics at study enrollment and 12 weeks postinjection. Improvement was analyzed based on 3-VD, UDI-6 questionnaire, VAS scores, and urodynamic parameters at week 12 postinjection compared to study enrollment. Results The study included 32 patients. Mean ± SD age was 56 ± 16. There were 27 women and 5 men. Nineteen patients had OAB without incontinence (OAB-dry) and 13 patients had OAB with incontinence (OAB-wet). In OAB-dry patients, mean ± SD urinary frequency dropped from 24 ± 11 to 10 ± 4 by week 12. In OAB-wet patients, mean ± SD urge incontinence episodes dropped from 7.9 ± 5 to 0 ± 2.6 by week 12. Mean UDI-6 and VAS scores improved significantly in both groups by week 12 (P = 0.0001). On comparing urodynamic parameters, OAB-wet patients showed significant decrease in maximum detrusor pressure during the voiding phase at week 12 compared to baseline values (P = 0.02). Conclusions Refractory idiopathic OAB patients without DOA on urodynamics may benefit from intradetrusor BTX-A.

Original languageEnglish
Pages (from-to)91-97
Number of pages7
JournalInternational Urology and Nephrology
Volume44
Issue number1
DOIs
StatePublished - Feb 1 2012

Fingerprint

Overactive Urinary Bladder
Type A Botulinum Toxins
Urodynamics
Visual Analog Scale
Equipment and Supplies
Urge Urinary Incontinence

Keywords

  • Botulinum toxin-A
  • Detrusor overactivity
  • Incontinence
  • Overactive bladder
  • Urodynamics

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity. / Kanagarajah, Prashanth; Ayyathurai, Rajinikanth; Caruso, Daniel J.; Gomez, Christopher; Gousse, Angelo E.

In: International Urology and Nephrology, Vol. 44, No. 1, 01.02.2012, p. 91-97.

Research output: Contribution to journalArticle

Kanagarajah, Prashanth ; Ayyathurai, Rajinikanth ; Caruso, Daniel J. ; Gomez, Christopher ; Gousse, Angelo E. / Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity. In: International Urology and Nephrology. 2012 ; Vol. 44, No. 1. pp. 91-97.
@article{5a0f2505199f43cb9718dc352e5081f0,
title = "Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity",
abstract = "Background To evaluate the efficacy of intradetrusor botulinum toxin-A (BTX-A) in idiopathic overactive bladder patients (OAB) refractory to antimuscarinic therapy, without detrusor overactivity (DOA) on urodynamics. Methods Patients with refractory idiopathic OAB without DOA on urodynamics were prospectively enrolled. Subjects completed a 3-day voiding diary (3-VD), urogenital distress inventory-6 questionnaire (UDI-6) and graded their quality of life on a 10-cm visual analog scale (VAS) prior to study enrollment and at week 12 postinjection. All patients underwent multichannel urodynamics at study enrollment and 12 weeks postinjection. Improvement was analyzed based on 3-VD, UDI-6 questionnaire, VAS scores, and urodynamic parameters at week 12 postinjection compared to study enrollment. Results The study included 32 patients. Mean ± SD age was 56 ± 16. There were 27 women and 5 men. Nineteen patients had OAB without incontinence (OAB-dry) and 13 patients had OAB with incontinence (OAB-wet). In OAB-dry patients, mean ± SD urinary frequency dropped from 24 ± 11 to 10 ± 4 by week 12. In OAB-wet patients, mean ± SD urge incontinence episodes dropped from 7.9 ± 5 to 0 ± 2.6 by week 12. Mean UDI-6 and VAS scores improved significantly in both groups by week 12 (P = 0.0001). On comparing urodynamic parameters, OAB-wet patients showed significant decrease in maximum detrusor pressure during the voiding phase at week 12 compared to baseline values (P = 0.02). Conclusions Refractory idiopathic OAB patients without DOA on urodynamics may benefit from intradetrusor BTX-A.",
keywords = "Botulinum toxin-A, Detrusor overactivity, Incontinence, Overactive bladder, Urodynamics",
author = "Prashanth Kanagarajah and Rajinikanth Ayyathurai and Caruso, {Daniel J.} and Christopher Gomez and Gousse, {Angelo E.}",
year = "2012",
month = "2",
day = "1",
doi = "10.1007/s11255-011-9979-9",
language = "English",
volume = "44",
pages = "91--97",
journal = "International Urology and Nephrology",
issn = "0301-1623",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity

AU - Kanagarajah, Prashanth

AU - Ayyathurai, Rajinikanth

AU - Caruso, Daniel J.

AU - Gomez, Christopher

AU - Gousse, Angelo E.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Background To evaluate the efficacy of intradetrusor botulinum toxin-A (BTX-A) in idiopathic overactive bladder patients (OAB) refractory to antimuscarinic therapy, without detrusor overactivity (DOA) on urodynamics. Methods Patients with refractory idiopathic OAB without DOA on urodynamics were prospectively enrolled. Subjects completed a 3-day voiding diary (3-VD), urogenital distress inventory-6 questionnaire (UDI-6) and graded their quality of life on a 10-cm visual analog scale (VAS) prior to study enrollment and at week 12 postinjection. All patients underwent multichannel urodynamics at study enrollment and 12 weeks postinjection. Improvement was analyzed based on 3-VD, UDI-6 questionnaire, VAS scores, and urodynamic parameters at week 12 postinjection compared to study enrollment. Results The study included 32 patients. Mean ± SD age was 56 ± 16. There were 27 women and 5 men. Nineteen patients had OAB without incontinence (OAB-dry) and 13 patients had OAB with incontinence (OAB-wet). In OAB-dry patients, mean ± SD urinary frequency dropped from 24 ± 11 to 10 ± 4 by week 12. In OAB-wet patients, mean ± SD urge incontinence episodes dropped from 7.9 ± 5 to 0 ± 2.6 by week 12. Mean UDI-6 and VAS scores improved significantly in both groups by week 12 (P = 0.0001). On comparing urodynamic parameters, OAB-wet patients showed significant decrease in maximum detrusor pressure during the voiding phase at week 12 compared to baseline values (P = 0.02). Conclusions Refractory idiopathic OAB patients without DOA on urodynamics may benefit from intradetrusor BTX-A.

AB - Background To evaluate the efficacy of intradetrusor botulinum toxin-A (BTX-A) in idiopathic overactive bladder patients (OAB) refractory to antimuscarinic therapy, without detrusor overactivity (DOA) on urodynamics. Methods Patients with refractory idiopathic OAB without DOA on urodynamics were prospectively enrolled. Subjects completed a 3-day voiding diary (3-VD), urogenital distress inventory-6 questionnaire (UDI-6) and graded their quality of life on a 10-cm visual analog scale (VAS) prior to study enrollment and at week 12 postinjection. All patients underwent multichannel urodynamics at study enrollment and 12 weeks postinjection. Improvement was analyzed based on 3-VD, UDI-6 questionnaire, VAS scores, and urodynamic parameters at week 12 postinjection compared to study enrollment. Results The study included 32 patients. Mean ± SD age was 56 ± 16. There were 27 women and 5 men. Nineteen patients had OAB without incontinence (OAB-dry) and 13 patients had OAB with incontinence (OAB-wet). In OAB-dry patients, mean ± SD urinary frequency dropped from 24 ± 11 to 10 ± 4 by week 12. In OAB-wet patients, mean ± SD urge incontinence episodes dropped from 7.9 ± 5 to 0 ± 2.6 by week 12. Mean UDI-6 and VAS scores improved significantly in both groups by week 12 (P = 0.0001). On comparing urodynamic parameters, OAB-wet patients showed significant decrease in maximum detrusor pressure during the voiding phase at week 12 compared to baseline values (P = 0.02). Conclusions Refractory idiopathic OAB patients without DOA on urodynamics may benefit from intradetrusor BTX-A.

KW - Botulinum toxin-A

KW - Detrusor overactivity

KW - Incontinence

KW - Overactive bladder

KW - Urodynamics

UR - http://www.scopus.com/inward/record.url?scp=84861126467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861126467&partnerID=8YFLogxK

U2 - 10.1007/s11255-011-9979-9

DO - 10.1007/s11255-011-9979-9

M3 - Article

VL - 44

SP - 91

EP - 97

JO - International Urology and Nephrology

JF - International Urology and Nephrology

SN - 0301-1623

IS - 1

ER -